The US Food and Drug Administration approved PLUVICTO for the treatment of PSMA-positive metastatic hormone-sensitive prostate cancer, which is expected to promote the drug as a new standard treatment for metastatic prostate cancer.
智通財經·07/31/2026 20:33:31
語音播報
The US Food and Drug Administration approved PLUVICTO for the treatment of PSMA-positive metastatic hormone-sensitive prostate cancer, which is expected to promote the drug as a new standard treatment for metastatic prostate cancer.